Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly Icos’ Cialis overtakes Viagra in France
The market share of Cialis in France has grown consistently since the product was introduced in Europe in February 2003. Since December 2004, Cialis has secured an additional
The market share of Cialis in France has grown consistently since the product was introduced in Europe in February 2003. Since December 2004, Cialis has secured an additional
The monoclonal antibodies will be provided by Antibodies by Design and the complementary peptide-based services and products from JPT. Each partner will offer the services of the other
The study, published in the journal Molecular Cancer Therapeutics and funded by Mars Incorporated, explains how pentameric procyanidin (pentamer), a compound found in cocoa, deactivates a number of
The joint UK National health Service (NHS) Greater Glasgow and University of Glasgow project, Glasgow Biomedicine, is part of ‘Medicine in Glasgow’, a unique collaboration aiming to develop
In a presentation at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, California, it was reported that CR011 selectively binds to GPNMB,
In previously published studies, PT-100 (talabostat) was shown to elicit anti-tumor T-cell responses in mice with fully functioning immune systems. The recently announced results have advanced this work
Kos acquired Azmacort from Aventis Pharmaceuticals in March 2004. As part of that acquisition, Aventis had a five-year manufacturing contract to produce Azmacort for Aeropharm Technology, a Kos
The double-blinded, placebo-controlled phase II clinical study was designed to evaluate the safety and efficacy of COL-3 for the treatment of rosacea, an inflammatory skin condition. At all
Memory and Roche entered into a collaboration for the development of PDE4 inhibitors for psychiatric and neurological indications in 2002. Roche has now decided not to pursue further
Peregrine Pharmaceuticals today announced that a paper titled “NHS76/PEP2, a Fully Human Vasopermeability-Enhancing Agent to Increase the Uptake and Efficacy of Cancer Chemotherapy,” The paper, which was published